{
  "id": 15916566,
  "title": "Researchers Validate Buoyant Mass for Cell Health Testing",
  "url": "https://urgent.news/2026/10/21/researchers-validate-buoyant-mass-for-cell-health-testing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-21T16:00:54.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/researchers-validate-buoyant-mass-for-cell-health-testing/"
  },
  "original_language": "en",
  "account": "Scientists from Massachusetts Institute of Technology (MIT) have validated the use of buoyant mass in predicting T cell health and patient response to immune checkpoint blockade (ICB) immunotherapy. The researchers discovered that measuring the buoyant mass of T cells proved to be more accurate in predicting patient response than traditional tumor mutational burden (TMB) approach.\n\nThe new technique could be useful for predicting cancer cell sensitivity to treatment and determining the productivity of cell cultures used in gene therapy manufacturing. Jiaquan Yu, a research scientist working in microfluidic engineering and cancer immunology at MIT, explains that the technique serves as a physical marker to predict the fate of T cells. T cells in the heavier group are better equipped to produce proteins, which indicates their fitness and ability to respond after activation against cancer in the context of ICB immunotherapy.\n\nThe team conducted a clinical study of 28 patients with melanoma receiving ICB, and the results showed that measuring buoyant mass was more effective than TMB in predicting treatment response. Yu emphasizes that people often underestimate simple non-molecular signatures, such as mass, volume, and density, while focusing heavily on gene and RNA-based biomarkers. In contrast, the researchers found that mass provides a result that integrates a wide range of information.",
  "summary": "Scientists have used measurement of buoyant mass by suspended microchannel resonator (SMR) technology to assess the immune fitness of T cells and predict patient response to immune checkpoint blockade (ICB). The post Researchers Validate Buoyant Mass for Cell Health Testing appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}